Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients
Abstract With the approval of new therapies targeting the PI3K pathway, the detection of PIK3CA mutations has become a key factor in treatment management for HR+/HER2− metastatic breast cancer (MBC). We developed multiplex digital PCR (dPCR) assays to detect and quantify PIK3CA mutations. A first sc...
Main Authors: | Julien Corné, Fanny Le Du, Véronique Quillien, Florence Godey, Lucie Robert, Héloïse Bourien, Angélique Brunot, Laurence Crouzet, Christophe Perrin, Claudia Lefeuvre-Plesse, Véronique Diéras, Thibault De la Motte Rouge |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-96644-6 |
Similar Items
-
Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
by: Julien Hadoux, et al.
Published: (2010-01-01) -
Patients’ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life
by: Léa Muzellec, et al.
Published: (2021-12-01) -
Enhance the effectiveness of PIK entrepreneurship training at PIK Langkawi
by: Nordin, Norrazlina
Published: (2021) -
From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin
by: Pascal Pujol, et al.
Published: (2019-07-01) -
How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors
by: Zoé Neviere, et al.
Published: (2020-02-01)